<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:chebi fb="0" ids="52290">mitogen</z:chebi>-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway has a master control role in various <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-related biological processes as cell growth, proliferation, differentiation, migration, and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain>It also regulates many transcription factors that control microRNAs (miRNAs) and their biosynthetic machinery </plain></SENT>
<SENT sid="2" pm="."><plain>To investigate on the still poorly characterised global involvement of miRNAs within the pathway, we profiled the expression of 745 miRNAs in three <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) cell lines after blocking the pathway with three different inhibitors </plain></SENT>
<SENT sid="3" pm="."><plain>This allowed the identification of two classes of post-treatment differentially expressed (DE) miRNAs: (1) common DE miRNAs in <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> lines after treatment with a specific inhibitor (class A); (2) DE miRNAs in a single <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> line after treatment with <z:hpo ids='HP_0000001'>all</z:hpo> three inhibitors (class B) </plain></SENT>
<SENT sid="4" pm="."><plain>By determining the molecular targets, biological roles, network position of chosen miRNAs from class A (miR-372, miR-663b, miR-1226*) and class B (miR-92a-1*, miR-135b*, miR-720), we experimentally demonstrated that they are involved in cell proliferation, migration, <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, and globally affect the regulation circuits centred on MAPK/ERK signaling </plain></SENT>
<SENT sid="5" pm="."><plain>Interestingly, the levels of miR-92a-1*, miR-135b*, miR-372, miR-720 are significantly higher in biopsies from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients than in <z:mpath ids='MPATH_458'>normal</z:mpath> controls; they also are significantly higher in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients with mutated KRAS than in those with <z:mp ids='MP_0002169'>wild-type</z:mp> genotypes (Wilcoxon test, p &lt; 0.05): the latter could be a downstream effect of ERK pathway overactivation, triggered by KRAS mutations </plain></SENT>
<SENT sid="6" pm="."><plain>Finally, our functional data strongly suggest the following miRNA/target pairs: miR-92a-1*/PTEN-SOCS5; miR-135b*/LATS2; miR-372/TXNIP; miR-663b/CCND2 </plain></SENT>
<SENT sid="7" pm="."><plain>Altogether, these results contribute to deepen current knowledge on still uncharacterized features of MAPK/ERK pathway, pinpointing new oncomiRs in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and allowing their translation into clinical practice and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> therapy </plain></SENT>
</text></document>